Development of the Oncology Opportunity Cost Assessment Tool : Item Generation and Content Validity Testing
PURPOSE: The purpose of this study was to develop the Oncology Opportunity Cost Assessment Tool (OOCAT), a survey instrument to evaluate the opportunity costs patients experience when seeking medical oncology care.
METHODS: Development of the OOCAT involved extensive patient engagement through both focus groups and interviews. First, the study team developed a list of opportunity cost concepts, which included patients' logistical and financial considerations related to seeking care. We conducted focus groups with patients to expand upon this list of concepts, and then developed a set of questions that incorporated all the concepts generated during the focus groups. To refine these questions, we next performed cognitive interviews with another set of patients to ensure content validity and clarity of instrument items, refining the OOCAT iteratively on the basis of feedback.
RESULTS: We engaged 23 participants (17 patients and six caregivers) across four focus groups and 17 participants in cognitive interviews. Focus group participants generated 112 concepts, which resulted in an initial OOCAT with 16 questions. Cognitive interviews resulted in modification of 12 questions and addition of two questions (related to coordination of transportation and impact on home responsibilities). The final OOCAT consisted of 18 items examining time requirements for appointments, financial implications of traveling to appointments for the patient and the caregiver, and logistical and quality-of-life challenges associated with traveling for appointments.
CONCLUSION: We developed the OOCAT, an instrument designed to evaluate patient-level opportunity costs of seeking medical oncology care. Further studies to validate the OOCAT are underway.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
JCO oncology practice - 18(2022), 3 vom: 17. März, Seite e360-e371 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Handley, Nathan R [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 22.04.2022 Date Revised 28.04.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1200/OP.21.00288 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM333450744 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM333450744 | ||
| 003 | DE-627 | ||
| 005 | 20231225221700.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/OP.21.00288 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1111.xml |
| 035 | |a (DE-627)NLM333450744 | ||
| 035 | |a (NLM)34807752 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Handley, Nathan R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Development of the Oncology Opportunity Cost Assessment Tool |b Item Generation and Content Validity Testing |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.04.2022 | ||
| 500 | |a Date Revised 28.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a PURPOSE: The purpose of this study was to develop the Oncology Opportunity Cost Assessment Tool (OOCAT), a survey instrument to evaluate the opportunity costs patients experience when seeking medical oncology care | ||
| 520 | |a METHODS: Development of the OOCAT involved extensive patient engagement through both focus groups and interviews. First, the study team developed a list of opportunity cost concepts, which included patients' logistical and financial considerations related to seeking care. We conducted focus groups with patients to expand upon this list of concepts, and then developed a set of questions that incorporated all the concepts generated during the focus groups. To refine these questions, we next performed cognitive interviews with another set of patients to ensure content validity and clarity of instrument items, refining the OOCAT iteratively on the basis of feedback | ||
| 520 | |a RESULTS: We engaged 23 participants (17 patients and six caregivers) across four focus groups and 17 participants in cognitive interviews. Focus group participants generated 112 concepts, which resulted in an initial OOCAT with 16 questions. Cognitive interviews resulted in modification of 12 questions and addition of two questions (related to coordination of transportation and impact on home responsibilities). The final OOCAT consisted of 18 items examining time requirements for appointments, financial implications of traveling to appointments for the patient and the caregiver, and logistical and quality-of-life challenges associated with traveling for appointments | ||
| 520 | |a CONCLUSION: We developed the OOCAT, an instrument designed to evaluate patient-level opportunity costs of seeking medical oncology care. Further studies to validate the OOCAT are underway | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Binder, Adam F |e verfasserin |4 aut | |
| 700 | 1 | |a Heyer, Arianna |e verfasserin |4 aut | |
| 700 | 1 | |a Granberg, Rachel E |e verfasserin |4 aut | |
| 700 | 1 | |a Davis, Garrison |e verfasserin |4 aut | |
| 700 | 1 | |a Nord, Garrison |e verfasserin |4 aut | |
| 700 | 1 | |a Gentsch, Alexzandra T |e verfasserin |4 aut | |
| 700 | 1 | |a Rising, Kristin L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JCO oncology practice |d 2020 |g 18(2022), 3 vom: 17. März, Seite e360-e371 |w (DE-627)NLM301053103 |x 2688-1535 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2022 |g number:3 |g day:17 |g month:03 |g pages:e360-e371 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1200/OP.21.00288 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2022 |e 3 |b 17 |c 03 |h e360-e371 | ||